AT394042B - Verfahren zur herstellung von neuen dihydropyridincarbonsaeure-derivaten - Google Patents

Verfahren zur herstellung von neuen dihydropyridincarbonsaeure-derivaten Download PDF

Info

Publication number
AT394042B
AT394042B AT0245485A AT245485A AT394042B AT 394042 B AT394042 B AT 394042B AT 0245485 A AT0245485 A AT 0245485A AT 245485 A AT245485 A AT 245485A AT 394042 B AT394042 B AT 394042B
Authority
AT
Austria
Prior art keywords
formula
compound
general formula
methyl
group
Prior art date
Application number
AT0245485A
Other languages
German (de)
English (en)
Other versions
ATA245485A (de
Original Assignee
Glaxo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT22383/84A external-priority patent/IT1175620B/it
Priority claimed from IT21460/85A external-priority patent/IT1187678B/it
Application filed by Glaxo Spa filed Critical Glaxo Spa
Publication of ATA245485A publication Critical patent/ATA245485A/de
Application granted granted Critical
Publication of AT394042B publication Critical patent/AT394042B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03B—MANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
    • C03B2205/00—Fibre drawing or extruding details
    • C03B2205/44—Monotoring or regulating the preform feed rate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT0245485A 1984-08-22 1985-08-22 Verfahren zur herstellung von neuen dihydropyridincarbonsaeure-derivaten AT394042B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT22383/84A IT1175620B (it) 1984-08-22 1984-08-22 Derivati piridinici
IT21460/85A IT1187678B (it) 1985-07-05 1985-07-05 Procedimento di preparazione di derivati eterociclici

Publications (2)

Publication Number Publication Date
ATA245485A ATA245485A (de) 1991-07-15
AT394042B true AT394042B (de) 1992-01-27

Family

ID=26327905

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0245485A AT394042B (de) 1984-08-22 1985-08-22 Verfahren zur herstellung von neuen dihydropyridincarbonsaeure-derivaten

Country Status (33)

Country Link
US (2) US4801599A (en])
JP (2) JPS6193162A (en])
KR (1) KR920004482B1 (en])
AT (1) AT394042B (en])
AU (1) AU578724B2 (en])
BE (1) BE903103A (en])
BG (1) BG60409B2 (en])
CA (1) CA1268180A (en])
CH (1) CH666684A5 (en])
CS (1) CS403091A3 (en])
CY (1) CY1494A (en])
DE (1) DE3529997C2 (en])
DK (1) DK165949C (en])
ES (5) ES8703839A1 (en])
FI (1) FI81568C (en])
FR (1) FR2569402B1 (en])
GB (1) GB2164336B (en])
GR (1) GR852016B (en])
HK (1) HK52990A (en])
HU (1) HU196754B (en])
IE (1) IE58486B1 (en])
LU (2) LU88267I2 (en])
MX (1) MX159974A (en])
NL (2) NL193065C (en])
NO (2) NO167142C (en])
NZ (1) NZ212895A (en])
PH (1) PH22014A (en])
PT (1) PT81000B (en])
SA (1) SA91120277B1 (en])
SE (1) SE459920B (en])
SG (1) SG40889G (en])
SK (1) SK278327B6 (en])
ZW (1) ZW13185A1 (en])

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
DE3675747D1 (de) * 1985-08-21 1991-01-03 Glaxo Spa 1,4-dihydropyridinverbindungen und ihre herstellung und pharmazeutische formulierung.
JPH0696552B2 (ja) * 1985-08-21 1994-11-30 グラクソ・ソシエタ・ペル・アツイオ−ニ 複素環式化合物
IT1204462B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
IT1204460B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
IT1204461B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
IT1233370B (it) * 1988-11-21 1992-03-27 Glaxo Spa Procedimento di preparazione di derivati diidropipiridinici utili nel trattamento di disturbi cardiovascolari
EP0395369B1 (en) 1989-04-27 1997-07-02 Canon Inc. Optical recording medium and process for production thereof
US5177202A (en) * 1990-10-09 1993-01-05 Merck & Co., Inc. 2-phenanthrenyl-carbapenems
US5196529A (en) * 1990-10-09 1993-03-23 Merck & Co., Inc. 2-phenanthrenyl carbapenem intermediates
US5132421A (en) * 1990-10-09 1992-07-21 Merck & Co., Inc. 2-naphthyl-carbapenem intermediates
US5132422A (en) * 1990-10-09 1992-07-21 Merck & Co., Inc. 2-naphthyl-carbapenem intermediates
US5356889A (en) * 1990-08-01 1994-10-18 Merck & Co., Inc. 2-(9-fluorenonyl)-carbapenem intermediates
US5144028A (en) * 1990-10-09 1992-09-01 Merck & Co., Inc. 2-(9-fluorenonyl)-carbapenem intermediates
US5208329A (en) * 1990-10-09 1993-05-04 Merck & Co., Inc. 2-biphenyl carbapenem intermediates
IT1244728B (it) * 1991-02-13 1994-08-08 Glaxo Spa Impiego medicamentoso di derivati diidropiridinici
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
DE60336485D1 (de) 2002-08-19 2011-05-05 Pfizer Kombinationstherapie gegen hyperproliferative erkrankungen
US7923467B2 (en) * 2003-05-30 2011-04-12 Ranbaxy Laboratories, Inc. Substituted pyrrole derivatives and their use as HMG-CO inhibitors
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
RU2007106714A (ru) * 2004-07-26 2008-09-10 Байер Шеринг Фарма Аг (De) Лечение легочной гипертензии путем ингаляции илопростата с препаратом микрочастиц
WO2006113309A1 (en) 2005-04-15 2006-10-26 Dr. Reddy's Laboratories Ltd. Lacidipine particles
US20070043088A1 (en) * 2005-08-16 2007-02-22 Eswaraiah Sajja Process for preparing lacidipine
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
ATE551059T1 (de) 2005-10-26 2012-04-15 Asahi Kasei Pharma Corp Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
US20080089947A1 (en) * 2006-08-18 2008-04-17 Knox Clayton D Calcium Influx Inhibitors in the Treatment of Ischemia
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
PL2705839T3 (pl) 2012-09-10 2018-07-31 Rivopharm Sa Farmaceutyczna kompozycja zawierająca lacydypinę i proces przygotowania
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN113574055B (zh) 2019-01-18 2024-07-23 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3207982A1 (de) * 1982-03-05 1983-09-08 Bayer Ag, 5090 Leverkusen Neue 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihrer verwendung in arzneimitteln

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455945A (en) * 1967-06-07 1969-07-15 Smithkline Corp 4-(carboxy (and carbo-lower alkoxy)phenyl)-1,4-dihydropyridines
DE2228363A1 (de) * 1972-06-10 1974-01-03 Bayer Ag 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB1409865A (en) * 1973-02-13 1975-10-15 Science Union & Cie Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them
US4307103A (en) * 1978-09-08 1981-12-22 Fujisawa Pharmaceutical Co., Ltd. Dihydropyridine derivative, processes for preparation thereof and pharmaceutical composition comprising the same
DE3018259A1 (de) * 1980-05-13 1981-11-19 Bayer Ag, 5090 Leverkusen 1,4-dihydropyridine mit unterschiedlichen substituenten in 2- und 6-position, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3207982A1 (de) * 1982-03-05 1983-09-08 Bayer Ag, 5090 Leverkusen Neue 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihrer verwendung in arzneimitteln

Also Published As

Publication number Publication date
AU4657685A (en) 1986-02-27
DK165949C (da) 1993-07-05
HUT40625A (en) 1987-01-28
CY1494A (en) 1990-02-16
ZW13185A1 (en) 1986-03-19
JPH0686430B2 (ja) 1994-11-02
ES546324A0 (es) 1987-03-01
NL8502296A (nl) 1986-03-17
ES552050A0 (es) 1987-09-01
ES8707931A1 (es) 1987-09-01
SE8503888L (sv) 1986-02-23
JPH0550506B2 (en]) 1993-07-29
FI853206A0 (fi) 1985-08-21
JPS6193162A (ja) 1986-05-12
ATA245485A (de) 1991-07-15
KR870002073A (ko) 1987-03-28
NO167142C (no) 1991-10-09
CS403091A3 (en) 1992-06-17
US4801599A (en) 1989-01-31
HU196754B (en) 1989-01-30
NO853293L (no) 1986-02-24
ES8703839A1 (es) 1987-03-01
SK278327B6 (en) 1996-11-06
SA91120277B1 (ar) 2006-05-15
SE459920B (sv) 1989-08-21
FR2569402B1 (fr) 1989-09-22
ES552049A0 (es) 1988-07-01
PT81000A (en) 1985-09-01
LU86047A1 (fr) 1986-02-28
KR920004482B1 (ko) 1992-06-05
FI81568C (fi) 1990-11-12
IE852054L (en) 1986-02-22
MX159974A (es) 1989-10-17
JPS6479152A (en) 1989-03-24
PH22014A (en) 1988-05-02
SG40889G (en) 1989-12-22
GR852016B (en]) 1985-12-19
PT81000B (pt) 1988-03-03
ES8707932A1 (es) 1987-09-01
DK165949B (da) 1993-02-15
BG60409B2 (bg) 1995-02-28
DE3529997C2 (de) 1996-01-18
SE8503888D0 (sv) 1985-08-20
ES8707930A1 (es) 1987-09-01
DE3529997A1 (de) 1986-03-06
DK378085D0 (da) 1985-08-20
CA1268180A (en) 1990-04-24
NO1999007I1 (no) 1999-04-23
LU88267I2 (en]) 1994-02-03
DK378085A (da) 1986-02-23
HK52990A (en) 1990-07-20
ES552051A0 (es) 1987-09-01
ES552048A0 (es) 1987-09-01
ES8802497A1 (es) 1988-07-01
BE903103A (fr) 1986-02-24
FI81568B (fi) 1990-07-31
NL193065B (nl) 1998-05-06
US5011848A (en) 1991-04-30
CH666684A5 (de) 1988-08-15
GB2164336B (en) 1988-06-08
IE58486B1 (en) 1993-09-22
AU578724B2 (en) 1988-11-03
FR2569402A1 (fr) 1986-02-28
NZ212895A (en) 1988-07-28
NO167142B (no) 1991-07-01
GB8520924D0 (en) 1985-09-25
NL980037I1 (nl) 1999-02-01
NL980037I2 (nl) 1999-03-01
GB2164336A (en) 1986-03-19
FI853206L (fi) 1986-02-23
NL193065C (nl) 1998-09-08

Similar Documents

Publication Publication Date Title
AT394042B (de) Verfahren zur herstellung von neuen dihydropyridincarbonsaeure-derivaten
EP0002208B1 (de) Nitrosubstituierte 1,4-Dihydropyridine, diese enthaltende Arzneimittel sowie deren Herstellung
DE69623631T2 (de) 4-aryl-1-phenylalkyl-1,2,3,6-tetrahydropyridine als neurothophe und neuroprotektive wirkstoffe
DE2508181A1 (de) 1,4-dihydropyridincarbonsaeurearal- kylester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2756226A1 (de) 1,4-dihydropyridin-verbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische mittel
DE2940833A1 (de) 2-methyl-dihydropyridin-verbindung, verfahren zu ihrer herstellung und sie enthaltendes pharmazeutisches mittel
DE3855017T2 (de) Verfahren zur Herstellung von kondensierten Pyridinverbindungen
DE3239273A1 (de) Tetrahydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE2841667A1 (de) Fluorhaltige 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
EP0080154B1 (de) N-Substituierte 2-Pyridylindole, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen, sowie ihre therapeutische Verwendung
EP0039863A1 (de) 1,4-Dihydropyridine mit unterschiedlichen Substituenten in 2- und 6-Position, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln
DE60015844T2 (de) Pyridin- und Piperidinderivate zur Behandlung von neurodegenerativen Erkrankungen
DE60206068T2 (de) Aralkyltetrahydropyridine, deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
DE2239815A1 (de) Verfahren zur herstellung von neuen 2-alkylamino-dihydropyridinen sowie ihre verwendung als arzneimittel
DE3826814A1 (de) Neue 6-fluor-3,5-dihydroxycarbonsaeuren und deren derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
DE3874394T2 (de) 1,3-dioxane.
DE3785695T2 (de) 1,4-dihydropyridinderivate.
DD235867A5 (de) Verfahren zur herstellung von 1,4-dihydropyridinen
DE3431862A1 (de) Neue 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DD299299A5 (de) Chromen-oder thiochromenderivate, verfahren zu deren herstellung und zwischenprodukte dafuer
AT394043B (de) Verfahren zur herstellung von neuen dihydropyridinderivaten
DE2242787A1 (de) Verfahren zur herstellung von neuen 3,4-dihydropyridonen sowie ihre verwendung als arzneimittel
DE2708142C3 (de) Verfahren zur Herstellung von substituierten Phenylacetonitrilen und neue Phenylacetonitrile
DE69008130T2 (de) Glutarsäurederivate und ihre Herstellung.
DE3432563A1 (de) Neue pyridylethyl-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimittel

Legal Events

Date Code Title Description
SZA Application filed for a certificate of protection

Free format text: SZ30/94, 941109

EZF Grant of a certificate of protection

Free format text: SZ 30/94, 941109

ELA Expired due to lapse of time